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Abstract 
Background: Cyclin D3, which induces progression through the G1 phase of the cell cycle, is a regulator of Cyclin-
dependent kinases 4 and 6. Previous studies revealed that abnormal expression of Cyclin D3 was found in many differ-
ent cancers. However, the role of Cyclin D3 in breast cancer (BC) remains unknown. The aim of this study is to examine 
the expression pattern of Cyclin D3 in BC and to evaluate its biological role and clinical significance in prognosis 
prediction. The mechanism involved is also evaluated.
Methods: Immunohistochemical staining was used to detect the expression of Cyclin D3. qRT-PCR was used to 
detect the mRNA level of Cyclin D3 in BC tissues and BC cell lines. Transwell assay was used to examine the role of 
Cyclin D3 in the migration and invasion of BC cells. Mass Spectrometry was used to search for the interacting protein 
with Cyclin D3. Co-Immunoprecipitation assay and GST-Pull Down assay were used to validate the interaction of 
Cyclin D3 and its interaction protein.
Results: Through detecting Cyclin D3 expression in 243 breast cancer patients’ tissue array, we found Cyclin D3 
expression was correlated with ER status (p = 0.000), PR status (p = 0.001), HER2 status (p = 0.002) and tumor differen-
tiation (p = 0.045). The Kaplan–Meier survival curves indicated that the disease free survival (DFS) was significantly 
poor in high Cyclin D3 expression BC patients (p = 0.004). Furthermore, expression of Cyclin D3 was significantly 
associated with BC prognosis and was shown to be an independent prognostic marker in breast cancer (p = 0.028). 
By IHC staining and qPCR detection, Cyclin D3 expression was found to be down-regulated both in BC tissues and in 
BC cell lines compared with the corresponding normal controls. Further investigation showed Cyclin D3 was involved 
in the metastasis of BC cells and physically interacted with actin in vivo and in vitro.
Conclusion: Our studies revealed that Cyclin D3 was upregulated in breast cancer and represented a novel predictor 
of BC prognosis.
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Background
D-type cyclins (i.e., Cyclin D1, D2, and D3) are regulators 
of the Cyclin-dependent kinases 4 and 6 (Cdk4 and Cdk6) 
and mediate the growth factor-induced progression 
through the G1 phase in the cell cycle [1]. CDKs promote 
cell cycle transitions in mammalian cells by phospho-
rylating key substrates cyclins [2]. Therefore, abnormal 
expression of cyclins was reported to be involved in many 
cancers progression. Cyclin D3 was widely expressed in 
many tumor cells. Cyclin D3 gene is amplified in blad-
der carcinoma in  situ [3]. Genomic changes disrupting 
the expression of Cyclin D3 are associated with aberrant 
growth of several human B-lymphoid malignancies [4]. 
Targeting Cyclin D3 by miR-138 could induce cell cycle 
arrest in hepatocellular carcinoma [5]. Furthermore, Cyc-
lin D3 is selectively required for proliferative expansion 
of germinal center B cells [6].
Breast cancer is the most common malignancy among 
women and represents an important public health issue 
[7]. Previous studies showed that Cyclin D1 and D3 are 
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overexpressed in human breast cancer cell lines and pri-
mary invasive breast cancers and Cyclin D3 frequently 
exceeded the expression of Cyclin D1 in ErbB2-positive 
cases [1]. E1AF promotes breast cancer cell cycle pro-
gression via upregulation of Cyclin D3 transcription [8]. 
Rapamycin causes a G1 arrest in HER-2-overexpressing 
breast cancer cells that is associated with a differential 
destabilization and subsequent down-regulation of Cyc-
lin D3 protein level [9]. All these studies showed that 
Cyclin D3 might play an important role in breast cancer.
In the present study, the relationship between Cyclin 
D3 and BC patients’ prognosis was uncovered. Breast 
cancer tissue array was employed to examine Cyclin D3 
expression in breast cancer patients and its relationship 
with the patients’ prognosis. We also detected the pro-
teins which interacted with Cyclin D3 to further elucidate 
the mechanism in Cyclin D3 mediated pathway in breast 
cancer.
Results
Cyclin D3 overexpression directly associates with poor 
disease‑free survival in breast cancer
First, we detected the expression of Cyclin D3 in the tis-
sue assay including 243 BC patients. Cyclin D3 expressed 
both in the nucleus and in the cytoplasm. In this study, a 
moderate/strong nucleus staining was defined as positive 
staining and there are 170 patients with high expression 
of Cyclin D3. A weak or negative staining was defined as 
negative staining and there are 73 patients with low Cyc-
lin D3 expression. Then the relationship between Cyclin 
D3 and clinical-pathological characteristics was assessed. 
Cyclin D3 expression displayed no correlationship with 
breast cancer patients’ age, menopausal status, tumor 
size, Ki67, vascular thrombosis, tumor size, node status 
or TNM status, while Cyclin D3 was positively corre-
lated with ER, PR and negatively correlated with HER2 
and tumor differention status (p < 0.05) (Additional file 1: 
Table S1).
All patients were followed up for at least 5 years. The 
results showed that DFS was significantly worse in 
breast cancer patients with high Cyclin D3 expression 
(p  =  0.01), although overall survival (OS) showed no 
statistical significance (p = 0.088) (Fig. 1b, c). To further 
validate these results in a broad range of clinical samples, 
we analyzed other two independent published dataset 
GSE2304 and GSE24450. Consistent with our clinical 
cohort result, we also noted significantly worse DFS of 
breast cancer patients in the Cyclin D3 high expression 
group (Fig. 1d, e).
When the correlation between DFS and each clinical-
pathological variables were examined in univariate anal-
ysis, age (HR 2.470; 95  % CI 1.032–5.911; p  =  0.042), 
lymph node status (HR 2.056; 95  % CI 1.068–3.992; 
p  =  0.031) and Cyclin D3 status (HR 5.545; 95  % CI 
1.705–18.032; p  =  0.004) were associated with higher 
risk of recurrence and reached statistical significance 
as expected  (Additional file  2: Table S2). However, only 
Cyclin D3 status remained statistically significant during 
multivariate analysis (Additional file  3: Table  S3). These 
data suggested that Cyclin D3 could serve as an inde-
pendent prognosis marker in breast cancer.
Expression patterns of Cyclin D3 in breast cancer tissues 
and cell lines
When we detected Cyclin D3 expression in tissue array, 
we found that expression of Cyclin D3 was higher in 
breast cancer tissues than in normal adjacent breast tis-
sues (Fig. 2a). It was further confirmed by qPCR assay. It 
showed that the mRNA level of Cyclin D3 was extremely 
high in the breast cancer tissues compared with the adja-
cent tissues (p < 0.05) (Fig. 2b). Expression of Cyclin D3 
was also detected in the breast cancer cell lines by qPCR 
and western blot. Cyclin D3 was higher in breast cancer 
cells than in the normal breast cell line MCF10A (Fig. 2c). 
These data indicated that Cyclin D3 highly expressed in 
breast cancer.
Cyclin D3 was involved in the metastasis of breast cancer
As Cyclin D3 was related with DFS of BC patients and it 
showed that Cyclin D3 was highly expressed in the high 
metastasis BC cell lines, such as MDA-MB231 and its 
high lung and bone metastatic subtypes (HM and BO), 
transwell assay was carried out to further examine the 
role of Cyclin D3 in BC metastasis. The results showed 
that the migration and invasion were significantly inhib-
ited when Cyclin D3 was down-regulated with its siRNA 
(p < 0.05). The knock down efficiency of siRNA targeted 
to Cyclin D3 was confirmed by western blot (Fig.  3). 
These data suggested that Cyclin D3 was involved in the 
metastasis of breast cancer.
Cyclin D3 interacted with actin in vivo and in vitro
Then we wondered how Cyclin D3 regulated the pro-
gression of breast cancer. First MS assay was used to 
search for Cyclin D3 interaction proteins. The MCF-7 
cells transfected with Cyclin D3 was lysed and the 
lysates were immunocripted with the antibody against 
Cyclin D3 then subjected to the immunoblot assay. The 
gel was stained with commassie blue dye. Compared 
to the control IgG, the unique band in the gel was cut 
off for the MS analysis. The results showed actin was 
among the Cyclin D3 immunocription complex. To vali-
date the physical interaction, CO-IP assay was carried 
out. We found that Cyclin D3 interacted with actin both 
in MCF-7 and in MDA-MB-231 (Fig. 4a). Furthermore, 
the interaction between GST-actin and Cyclin D3 in 
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Fig. 1 Kaplan–Meier survival curves of patients with breast cancer based on Cyclin D3 expression status. a Cyclin D3 immunostaining was 
determined in breast cancer and divided into low expression (upper) and high expression (lower). All immunohistochemical photomicrographs are 
magnified 400×. b Relationship between Cyclin D3 expression and disease free survival (DFS) overall survival (OS). p values were calculated using 
the unadjusted log-rank test. d Relationship between Cyclin D3 expression and overall survival (OS). p values were calculated using the unadjusted 
log-rank test. c High expression of Cyclin D3 associated with poor survival in breast cancer patients. Patients data obtained from data set GSE24450 
were stratified by median level of Cyclin D3 expression and analyzed by Kaplan–Meier curves. e High expression of Cyclin D3 associated with 
proor survival in breast cancer patients. Patients data obtained from data set GSE2304 were stratified by median level of Cyclin D3 expression and 
analyzed by Kaplan–Meier curves
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cells lysates was also detectable in the GST-PULL down 
assay in  vitro (Fig.  4b lane 4, about 30KD). Cyclin D1 
was used as a negative control. It suggested that Cyclin 
D3 directly interacted with actin. The physical inter-
action was also confirmed by confocal immunofluo-
rescence (Fig.  4c). These data indicated that Cyclin D3 
interacted with actin in vivo and in vitro. As we known, 
actin was involved in the movement of cells and could 
regulate the invasion of cancer cells. We speculated that 
Cyclin D3 might affect the metastasis of BC through 
interating with actin. However, it still needs further 
investigation.
Fig. 2 Cyclin D3 expression profiles in breast cancer tissues and cell lines. a Cyclin D3 immunostaining was performed in 50 pairs of BC tumor 
tissues and ANCT normal tissues. All immunohistochemical photomicrographs are magnified 400×. bComparison of Cyclin D3 expression levels 
between 20 pairs of BC tumor tissues and ANCT normal tissues by qRT-PCR analysis. GAPDH was used as an internal control (p < 0.01). c Compari-
son of Cyclin D3 expression levels between 9 BC cell lines and normal MCF10A cells by qRT-PCR analysis and western blot. GAPDH was used as an 
internal control. HM lung highly metastasis, BO bone highly metastasis
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Discussion
D-type cyclins (D1, D2, and D3) bind cyclin dependent 
kinases 4 and 6 (CDK4/6), and the activity of cyclin D/
CDK complexes promotes entry into cell cycle [10, 11]. 
Aberrant cell cycle regulation is a common thread to 
all forms of cancers [12]. Deregulated expression of all 
D-type cyclins is frequently observed in hematopoietic 
malignancies [13] [14, 15].
Compared to cyclin D1 and cyclin D2, little was known 
about Cyclin D3’s function. Previous researches dem-
onstrated that Cyclin D3 interacted with p58PITSLRE, 
a member of the PITSLRE protein kinase family and 
Fig. 3 Cyclin D3 was involved in the metastasis of breast cancer. MDA-MB231 cells were transfected with siRNA targeting Cyclin D3 or control 
vectors. After 6 h, transwell assays were performed as described. Crystal violet staining of migrating and invading cells is shown. Data are expressed 
as the mean ± SEM of the number of invading cells in more than five separate areas. *p < 0.05 versus vector controls (n = 3 experiments). The 
efficiency of knock down was detected by western blot. GAPDH was used as a loading control
Page 6 of 9Chi et al. Cancer Cell Int  (2015) 15:89 
evidently enhanced its kinase activity [16]. Also, Cyc-
lin D3 interacts with both retinoic acid receptor (RAR) 
and cellular retinoic acid-binding protein II to form a 
ternary complex and up-regulate retinoic acid-mediated 
transcription [17]. Cycin D3 could interact with vita-
min D receptor and regulates its transcription activity 
Fig. 4 Cyclin D3 interacted with actin in vivo and in vitro. a MCF-7 or MDA-MB231 cells were transfected with HA-actin. 48 h later, cells were 
lysed and immunoprecipitated with HA antibody or Cyclin D3 antibody, then subjected to SDS-PAGE and detected with Cyclin D3 antibody or HA 
antibody. b GST-actin (70KD) was in vitro translated, [35S]methionine labeled, preimmobilized onto glutathione-Sepharose 4B beads, and incubated 
with lyses of MCF-7 cells transfected with Cyclin D3 (30KD) or Cyclin D1 (30KD). Binding proteins were subjected to SDS-PAGE and visualized by 
phosphorimaging. c MCF-7 cells were subjected to immunoflurorescent staining assay. Cells were fixed and reacted with a mouse monoclonal anti-
Cyclin D3 antibody and a rabbit polyclonal anti-actin antibody. The secondary antibodies were anti-rabbit IgG-conjugated to fluorescein isothiocy-
anate and anti-mouse IgG-conjugated to rhodamine red. The images were captured with a Leica confocal microscope and software provided by 
Leica
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[18]. Previous data have suggested that Notch signal-
ing directly regulates Cyclin D3 expression and block-
ing Cyclin D3 expression by γ-secretase inhibition of 
Notch signaling prevents cell cycle progression in human 
T-ALL cell lines in  vitro [19]. And abnormal Cyclin D3 
was also found in other cancers, such as leukemia [20], 
HCC [21], gliomas [22], bladder carcinoma [23], prostate 
cancer [24] and osteosaroma [25]. These data suggested 
that D-type cyclins and/or their downstream interact-
ing partners could be attractive therapeutic targets in the 
cancer.
We demonstrated here that Cyclin D3 was up-regulated 
in breast cancer. Cyclin D3 expression was positively cor-
related with ER, PR and negatively correlated with HER2 
and tumor differention status (p < 0.05). DFS was signifi-
cantly worse in breast cancer patients with high Cyclin 
D3 expression (p = 0.01).
When the correlation between DFS and each clinical-
pathological variables were examined in univariate anal-
ysis, Cyclin D3 status (HR 5.545; 95 % CI 1.705–18.032; 
p  =  0.004) were associated with higher risk of recur-
rence and remained statistically significant during multi-
variate analysis. It suggested that Cyclin D3 could be an 
independent factor for predicting the prognosis of BC 
patients.
Further investigation revealed that Cyclin D3 prompted 
the migration and invasion of breast cancer cells. MS 
analysis suggested Cyclin D3 interacted with actin and it 
was further validated by CO-IP assay and GST-Pull down 
assay.
As we known, cell migration requires dynamic remod-
eling of the actomyosin network [26]. It is reported 
that decreased beta-actin expression in normal corneal 
stroma clearly disrupts the cytoskeletal structure and 
functions, including keratocyte motility and wound 
healing [27]. A 130-kDa protein 4.1B was found to reg-
ulate cell adhesion, spreading, and migration of mouse 
embryo fibroblasts by influencing actin cytoskeleton 
organization [28]. Furthermore, RAGE-binding S100A8/
A9 promoted the migration and invasion of human 
breast cancer cells through actin polymerization [29]. 
Actin was possibly involved in the cell dynamic remod-
eling and movement. Previous studies showed that 
cGMP-dependent protein kinase I beta regulated breast 
cancer cell migration and invasion via interaction with 
the actin/myosin-associated protein caldesmon [30]. 
Besides, actins are localized both in cytoplasm and in 
nucleus. The nuclear actins combine with actin bind-
ing protein and polymeraseIIto form the transcriptional 
machinery and regulate multiple gene transcription 
[31]. Base on our results, Cyclin D3 and actin were 
mainly co-localized in the cellular nucleus. Nuclear actin 
was reported to be involved in the gene transcription 
regulation, so we speculated that Cyclin D3 promoted 
the progression and invasion of breast cancer by inter-
acting with actin to regulate some metastasis related 
genes or oncogene transcription. However it needs fur-
ther investigation.
In this study, we provided the evidence that Cyclin D3 
predicted disease-free survival in breast cancer and could 




A total of 243 primary breast cancer samples of stage I 
to III invasive ductal carcinoma cases and ANCT were 
collected randomly at the Department of Breast Surgery 
in Fudan University Shanghai Cancer Center (FDUSCC, 
Shanghai, P. R. China). Each case was given a unique 
identifier and linked to a database containing clinical-
pathological data. ANCT means the normal breast tis-
sue and it was diagnosed by the pathologists through 
H.E. staining. The tumors were assessed according to 
the WHO classification by two academic pathologists. 
In addition, the pathological data including (ER, PR), 
HER2, P53 and Ki67 status/expression were assessed and 
diagnosed by the pathologists based on the ASCO breast 
cancer guideline. Patient information and tumor pathol-
ogy are summarized. This study was approved by the 
Ethical Committee of Fudan University Shanghai Cancer 
Center for Clinical Research (Reference number: 050432-
4-1212B). The written informed consents were obtained 
from all the patients.
Immunohistochemical (IHC) staining
A total of 243 FFPE blocks of breast cancer tissues and 
ANCT were collected for tissue microarrays. Two breast 
cancer tissue cores and two ANCT cores from the same 
patient’s FFPE blocks were arranged on recipient paraffin 
block (with a 1-mm core per specimen). Paraffin sections 
(3-μm thick) were deparaffinized in xylene and rehy-
drated in a graded alcohol series, boiled with 10 mmol/L 
of citrate buffer (pH 6) for 15 min and pre-incubated in 
blocking solution (10 % normal goat sera) for 1 h at room 
temperature. The steps were performed using the Envi-
sion two-step method. The Envision and DAB Color 
Kit was purchased from Gene Tech Company Limited 
(Shanghai, China). A mouse anti-human monoclonal 
antibody against Cyclin D3 was used at a 1:100 dilution. 
PBS (phosphate buffered saline) was used as a negative 
control. The tissue microarray slides were concurrently 
evaluated by two of the authors. For Cyclin D3 protein 
in this study, a moderate/strong nucleus staining was 
defined as positive staining, and a weak or negative stain-
ing was defined as negative staining.
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Cell culture and regents
Nine breast cell lines were obtained from cell bank of our 
lab. MCF-7, BCAP 37 and BT474 cells were grown using 
1640 medium. MDA-MB231, MDA-MB231BO MDA-
MB231HM cells were cultured using F15. MDA-MB436 
and MDA-MB468 cells were cultured with DMEM 
medium. MCF10A were cultured with F12/DMEM 1:1 
medium. All medium are with 10 % FBS, 100 ug/ml peni-
cillin and 100 ug/ml streptomycin. The cells were cul-
tured at 37 °C and 5 % CO2.
RNA extraction and quantitative RT‑PCR
Total RNA was extracted using TRIzol reagent (Invitro-
gen). After converting total RNA to cDNA in a reverse 
transcription (RT) reaction, qPCR were used to quantify 
the mRNA expression levels. To detect Cyclin D3 expres-
sion, we used the SYBR-Green method. GAPDH was 
used as an internal control. 2−∆Ct values were used to 
determine their relative expression.
Transwell assay
Cell invasion was assayed using BD BioCoat Growth Fac-
tor Reduced (GFR) Matrigel Invasion Chambers (BD, 
CA). Transfected MDA-MB231 cells (0.5  ml; 5  ×  104 
cells/ml) were added to the inside of the inserts and incu-
bated for 3 h. After incubation, non-invading cells were 
removed from the upper surface of the membrane using 
cotton-tipped swabs. The cells on the lower surface of the 
membrane were stained with Crystal violet and counted 
in the central field of triplicate membranes.
Immunoprecipitation and western blotting
MCF-7 and MDA-MB231cells were transfected with 4 
μg of HA-actin. Approximately 48  h after transfection, 
cells were washed with ice-cold phosphate- buffered 
saline and solubilized with 1  ml of coimmunoprecipita-
tion buffer (50  mM Tris–HCl (pH 7.5), 150  mM NaCl, 
0.1 % Nonidet P-40, 5 mM EDTA, 5 mM EGTA, 15 mM 
MgCl2, 60  mM-glycerophosphate, 0.1  mM sodium 
orthovanadate, 0.1 mM NaF, 0.1 mM benzamide, 10 μg/
ml aprotinin, 10 μg/ml leupeptin, 1 mM PMSF). Deter-
gent-insoluble materials were removed by centrifugation. 
Cell lysates were incubated with 2 μg of relevant anti-
body at 4  °C for 2 h. Pre-equilibrated protein G-agarose 
beads were added and collected by centrifugation after 
incubation overnight and then gently washed three times 
with the lysis buffer. The bound proteins were eluted and 
analyzed using Western blots. An antibody to GAPDH 
was used to ensure equivalent loading.
GST pull‑down assay
GST-actin was purified from bacterial lysates using 
glutathione-agarose beads (Amersham Biosciences). 
His-Cyclin D1, His-Cyclin D proteins were puri-
fied from Escherichia coli using high performance 
nickel-Sepharose (GE Healthcare). 20 μl of His-tagged 
proteins were incubated with 5 μl (about 10 μg) of 
GST-tagged fusion protein or control protein (GST) 
in 300 μl of lysis buffer and rotated for 3–5  h at 4  °C. 
Pre-equilibrated glutathione-sepharose 4B beads were 
added and collected by centrifugation after incubation 
overnight and then gently washed three times with the 
lysis buffer. The beads were resuspended in SDS-PAGE 
sample buffer, boiled for 5  min, electrophoresed on a 
10 % SDSpolyacrylamide gel, and analyzed by Western 
blot.
Statistical analysis
Analyses were performed using SPSS software. 
Kaplan–Meier survival analysis was also performed 
using SPSS. Differences with p values  <0.05 are con-
sidered significant. Univariate analysis was used in 
multivariate analysis on the basis of Cox proportional 
hazards model. Two-sided p values were calculated 
and a probability level of 0.05 was chosen for statistical 
significance.
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